Cargando…
Neuroprotective effect of diosgenin in a mouse model of diabetic peripheral neuropathy involves the Nrf2/HO-1 pathway
BACKGROUND: Diabetic peripheral neuropathy (DPN) is one of the most common chronic complications of diabetes. Diosgenin is a natural steroidal saponin with a variety of beneficial effects, including antidiabetic effects, and is a raw material for the synthesis of carrier hormones. In our study, we a...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7184706/ https://www.ncbi.nlm.nih.gov/pubmed/32336289 http://dx.doi.org/10.1186/s12906-020-02930-7 |
_version_ | 1783526636271960064 |
---|---|
author | Leng, Jinhong Li, Xiaohua Tian, He Liu, Chang Guo, Yining Zhang, Su Chu, Yang Li, Jian Wang, Ying Zhang, Ling |
author_facet | Leng, Jinhong Li, Xiaohua Tian, He Liu, Chang Guo, Yining Zhang, Su Chu, Yang Li, Jian Wang, Ying Zhang, Ling |
author_sort | Leng, Jinhong |
collection | PubMed |
description | BACKGROUND: Diabetic peripheral neuropathy (DPN) is one of the most common chronic complications of diabetes. Diosgenin is a natural steroidal saponin with a variety of beneficial effects, including antidiabetic effects, and is a raw material for the synthesis of carrier hormones. In our study, we aimed to assess the antioxidant effects of diosgenin in diabetic mice. METHODS: Male C57 mice were fed a high-fat diet for 8 weeks and intraperitoneally injected with streptozotocin (STZ) at a dose of 100 mg/kg for 2 consecutive days. Eligible mice were divided into the normal control group (CON), diabetic group (DM), low-dose diosgenin (50 mg/kg) group (DIO50) and high-dose diosgenin (100 mg/kg) group (DIO100). Treatment was started 6 weeks after the induction of diabetes by STZ and continued for 8 weeks. Blood sugar and body weight were monitored dynamically. The behavioural effects of diosgenin were detected by a hot tail immersion test and paw tactile responses. HE staining was used to evaluate edema and degeneration of the sciatic nerve. The levels of SOD, MDA and GPx were tested according to the instructions of the respective kits. The levels of Nrf2, HO-1 and NQO1 were detected by immunofluorescence and Western blotting. Statistical analysis was performed using SPSS, and P < 0.05 was considered statistically significant. RESULTS: Diosgenin decreased the blood glucose levels and increased the body weight of diabetic mice. There was a significant increase in the tail withdrawal latency of diabetic animals, and mechanical hyperalgesia was significantly alleviated after diosgenin treatment. Histopathological micrographs of HE-stained sciatic nerves showed improvement after diosgenin treatment. Diosgenin attenuated the level of MDA but increased the activities of SOD and GPx. Diosgenin increased the expression of Nrf2, HO-1 and NQO1. CONCLUSIONS: Our results demonstrate that diosgenin can ameliorate behavioural and morphological changes in DPN by reducing oxidative stress. The Nrf2/HO-1 signalling pathway was involved in its neuroprotective effects. |
format | Online Article Text |
id | pubmed-7184706 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-71847062020-04-30 Neuroprotective effect of diosgenin in a mouse model of diabetic peripheral neuropathy involves the Nrf2/HO-1 pathway Leng, Jinhong Li, Xiaohua Tian, He Liu, Chang Guo, Yining Zhang, Su Chu, Yang Li, Jian Wang, Ying Zhang, Ling BMC Complement Med Ther Research Article BACKGROUND: Diabetic peripheral neuropathy (DPN) is one of the most common chronic complications of diabetes. Diosgenin is a natural steroidal saponin with a variety of beneficial effects, including antidiabetic effects, and is a raw material for the synthesis of carrier hormones. In our study, we aimed to assess the antioxidant effects of diosgenin in diabetic mice. METHODS: Male C57 mice were fed a high-fat diet for 8 weeks and intraperitoneally injected with streptozotocin (STZ) at a dose of 100 mg/kg for 2 consecutive days. Eligible mice were divided into the normal control group (CON), diabetic group (DM), low-dose diosgenin (50 mg/kg) group (DIO50) and high-dose diosgenin (100 mg/kg) group (DIO100). Treatment was started 6 weeks after the induction of diabetes by STZ and continued for 8 weeks. Blood sugar and body weight were monitored dynamically. The behavioural effects of diosgenin were detected by a hot tail immersion test and paw tactile responses. HE staining was used to evaluate edema and degeneration of the sciatic nerve. The levels of SOD, MDA and GPx were tested according to the instructions of the respective kits. The levels of Nrf2, HO-1 and NQO1 were detected by immunofluorescence and Western blotting. Statistical analysis was performed using SPSS, and P < 0.05 was considered statistically significant. RESULTS: Diosgenin decreased the blood glucose levels and increased the body weight of diabetic mice. There was a significant increase in the tail withdrawal latency of diabetic animals, and mechanical hyperalgesia was significantly alleviated after diosgenin treatment. Histopathological micrographs of HE-stained sciatic nerves showed improvement after diosgenin treatment. Diosgenin attenuated the level of MDA but increased the activities of SOD and GPx. Diosgenin increased the expression of Nrf2, HO-1 and NQO1. CONCLUSIONS: Our results demonstrate that diosgenin can ameliorate behavioural and morphological changes in DPN by reducing oxidative stress. The Nrf2/HO-1 signalling pathway was involved in its neuroprotective effects. BioMed Central 2020-04-26 /pmc/articles/PMC7184706/ /pubmed/32336289 http://dx.doi.org/10.1186/s12906-020-02930-7 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Leng, Jinhong Li, Xiaohua Tian, He Liu, Chang Guo, Yining Zhang, Su Chu, Yang Li, Jian Wang, Ying Zhang, Ling Neuroprotective effect of diosgenin in a mouse model of diabetic peripheral neuropathy involves the Nrf2/HO-1 pathway |
title | Neuroprotective effect of diosgenin in a mouse model of diabetic peripheral neuropathy involves the Nrf2/HO-1 pathway |
title_full | Neuroprotective effect of diosgenin in a mouse model of diabetic peripheral neuropathy involves the Nrf2/HO-1 pathway |
title_fullStr | Neuroprotective effect of diosgenin in a mouse model of diabetic peripheral neuropathy involves the Nrf2/HO-1 pathway |
title_full_unstemmed | Neuroprotective effect of diosgenin in a mouse model of diabetic peripheral neuropathy involves the Nrf2/HO-1 pathway |
title_short | Neuroprotective effect of diosgenin in a mouse model of diabetic peripheral neuropathy involves the Nrf2/HO-1 pathway |
title_sort | neuroprotective effect of diosgenin in a mouse model of diabetic peripheral neuropathy involves the nrf2/ho-1 pathway |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7184706/ https://www.ncbi.nlm.nih.gov/pubmed/32336289 http://dx.doi.org/10.1186/s12906-020-02930-7 |
work_keys_str_mv | AT lengjinhong neuroprotectiveeffectofdiosgenininamousemodelofdiabeticperipheralneuropathyinvolvesthenrf2ho1pathway AT lixiaohua neuroprotectiveeffectofdiosgenininamousemodelofdiabeticperipheralneuropathyinvolvesthenrf2ho1pathway AT tianhe neuroprotectiveeffectofdiosgenininamousemodelofdiabeticperipheralneuropathyinvolvesthenrf2ho1pathway AT liuchang neuroprotectiveeffectofdiosgenininamousemodelofdiabeticperipheralneuropathyinvolvesthenrf2ho1pathway AT guoyining neuroprotectiveeffectofdiosgenininamousemodelofdiabeticperipheralneuropathyinvolvesthenrf2ho1pathway AT zhangsu neuroprotectiveeffectofdiosgenininamousemodelofdiabeticperipheralneuropathyinvolvesthenrf2ho1pathway AT chuyang neuroprotectiveeffectofdiosgenininamousemodelofdiabeticperipheralneuropathyinvolvesthenrf2ho1pathway AT lijian neuroprotectiveeffectofdiosgenininamousemodelofdiabeticperipheralneuropathyinvolvesthenrf2ho1pathway AT wangying neuroprotectiveeffectofdiosgenininamousemodelofdiabeticperipheralneuropathyinvolvesthenrf2ho1pathway AT zhangling neuroprotectiveeffectofdiosgenininamousemodelofdiabeticperipheralneuropathyinvolvesthenrf2ho1pathway |